Cited 0 times in
Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2014-12-19T16:59:59Z | - |
dc.date.available | 2014-12-19T16:59:59Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90590 | - |
dc.description.abstract | OBJECTIVE: Temsirolimus, an inhibitor of the mammalian target of rapamycin, is approved for treatment of patients with advanced renal cell carcinoma in the USA and Europe. Temsirolimus was not yet evaluated in East Asian patients. METHODS: This non-randomized Phase II study enrolled 82 patients with advanced renal cell carcinoma [20 (24%) Japanese, 30 (37%) Korean and 32 (39%) Chinese patients; median age (range): 55 (26-83) years]. Most (71%) received prior systemic therapy for metastatic disease; two-thirds were intermediate risk. Six Japanese patients received intravenous temsirolimus 20 mg/m(2) weekly for tolerability assessment (Group A); the remaining 76 received a 25 mg flat dose weekly (Group B). Temsirolimus was dosed once weekly. Primary efficacy end point was the Response Evaluation Criteria in Solid Tumors-defined clinical benefit rate in the intent-to-treat population. RESULTS: In the entire population, regardless of treatment group, the clinical benefit rate was 48% (95% confidence interval: 36, 59). Objective response rate was 11% (95% confidence interval: 5, 20), median progression-free survival was 7.3 months (95% confidence interval: 4.0, 9.2) and median time to treatment failure was 5.4 months (95% confidence interval: 3.5, 7.4). No patient in Group A demonstrated dose-limiting toxicity. The most frequent Grade 3 or 4 drug-related adverse events were anemia, hyperglycemia, hypophosphatemia and stomatitis (5% each). Serious adverse events reported in ≥ 5% of patients were pneumonia (9%) and interstitial lung disease (7%). Temsirolimus and its major metabolite, sirolimus, were long-lived throughout the dosage interval, with no evidence of accumulation. CONCLUSION: Temsirolimus was well tolerated and showed promising activity in Japanese, Korean and Chinese patients with advanced renal cell carcinoma. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anemia/chemically induced | - |
dc.subject.MESH | Antineoplastic Agents/administration & dosage | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/pharmacokinetics | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group* | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyperglycemia/chemically induced | - |
dc.subject.MESH | Hypophosphatemia/chemically induced | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Outpatients | - |
dc.subject.MESH | Protein Kinase Inhibitors/therapeutic use | - |
dc.subject.MESH | Sirolimus/administration & dosage | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives* | - |
dc.subject.MESH | Sirolimus/pharmacokinetics | - |
dc.subject.MESH | Sirolimus/therapeutic use | - |
dc.subject.MESH | Stomatitis/chemically induced | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yan Sun | - |
dc.contributor.googleauthor | Sun Rha | - |
dc.contributor.googleauthor | Se-Hoon Lee | - |
dc.contributor.googleauthor | Jun Guo | - |
dc.contributor.googleauthor | Takeshi Ueda | - |
dc.contributor.googleauthor | Shukui Qin | - |
dc.contributor.googleauthor | Seiji Naito | - |
dc.contributor.googleauthor | Maria Cincotta | - |
dc.contributor.googleauthor | Kota Tokushige | - |
dc.contributor.googleauthor | Hideyuki Akaza | - |
dc.identifier.doi | 22844126 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 22844126 | - |
dc.identifier.url | http://jjco.oxfordjournals.org/content/42/9/836.long | - |
dc.subject.keyword | Adult | - |
dc.subject.keyword | Aged | - |
dc.subject.keyword | Anemia/chemically induced | - |
dc.subject.keyword | Antineoplastic Agents/administration & dosage | - |
dc.subject.keyword | Antineoplastic Agents/adverse effects | - |
dc.subject.keyword | Antineoplastic Agents/pharmacokinetics | - |
dc.subject.keyword | Antineoplastic Agents/therapeutic use* | - |
dc.subject.keyword | Asian Continental Ancestry Group* | - |
dc.subject.keyword | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.keyword | Disease-Free Survival | - |
dc.subject.keyword | Drug Administration Schedule | - |
dc.subject.keyword | Female | - |
dc.subject.keyword | Humans | - |
dc.subject.keyword | Hyperglycemia/chemically induced | - |
dc.subject.keyword | Hypophosphatemia/chemically induced | - |
dc.subject.keyword | Kaplan-Meier Estimate | - |
dc.subject.keyword | Kidney Neoplasms/drug therapy* | - |
dc.subject.keyword | Male | - |
dc.subject.keyword | Middle Aged | - |
dc.subject.keyword | Outpatients | - |
dc.subject.keyword | Protein Kinase Inhibitors/therapeutic use | - |
dc.subject.keyword | Sirolimus/administration & dosage | - |
dc.subject.keyword | Sirolimus/adverse effects | - |
dc.subject.keyword | Sirolimus/analogs & derivatives* | - |
dc.subject.keyword | Sirolimus/pharmacokinetics | - |
dc.subject.keyword | Sirolimus/therapeutic use | - |
dc.subject.keyword | Stomatitis/chemically induced | - |
dc.subject.keyword | Treatment Outcome | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 42 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 836 | - |
dc.citation.endPage | 844 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.42(9) : 836-844, 2012 | - |
dc.identifier.rimsid | 32855 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.